US 11,883,437 B2
Xenograft soft tissue implants and methods of making
Arnd Wilhelmi, Forchheim (DE); Silke Schreiner, Erlangen (DE); Jake Michaelson, Gainesville, FL (US); Steven Moore, Apex, NC (US); Jennifer Faleris, Lowell, FL (US); and Anne Reinlein, Bamberg (DE)
Assigned to Tutogen Medical GmbH, Neunkirchen am Brand (DE)
Filed by Tutogen Medical GmbH, Neunkirchen am Brand (DE)
Filed on Jun. 10, 2022, as Appl. No. 17/838,001.
Application 17/013,159 is a division of application No. 16/113,951, filed on Aug. 27, 2018, granted, now 10,765,703.
Application 16/113,951 is a division of application No. 13/839,440, filed on Mar. 15, 2013, granted, now 10,076,543.
Application 17/838,001 is a continuation of application No. 17/013,159, filed on Sep. 4, 2020, granted, now 11,382,933.
Application 13/839,440 is a continuation in part of application No. PCT/EP2012/000124, filed on Jan. 12, 2012.
Claims priority of application No. 1020110086048 (DE), filed on Jan. 14, 2011.
Prior Publication US 2022/0296651 A1, Sep. 22, 2022
Int. Cl. A61K 35/36 (2015.01); A61L 27/36 (2006.01)
CPC A61K 35/36 (2013.01) [A61L 27/362 (2013.01); A61L 27/3687 (2013.01)] 18 Claims
 
1. A surgical method of using a graft comprising: implanting the graft during surgery, for treatment of a human patient; wherein the graft is prepared by:
(a) providing a bovine dermis having a native dermal matrix;
(b) treating the bovine dermis with an aqueous alkaline sodium sulfide solution for at least 1 hour, wherein the aqueous alkaline sodium sulfide solution comprises 0.01% to 1.5% by weight of sodium sulfide and 0.001 M to 0.5 M sodium hydroxide, wherein a pH of the aqueous alkaline sodium sulfide solution is greater than 10;
(c) treating the bovine dermis with a saline solution at least once;
(d) treating the bovine dermis with an aqueous hydrogen peroxide solution at least once;
(e) dehydrating the bovine dermis via solvent dehydration with a solvent starting with a first concentration of the solvent and finishing with a second concentration of the solvent, higher than the first concentration of the solvent; and
(f) maintaining a histoarchitecture of the native dermal matrix of the bovine dermis, wherein the graft is non-crosslinked.